Stocks · News reference
Canaccord Genuity analyst William Plovanic maintains Artivion (NYSE:AORT) with a Buy and raises the price target from $39 to $40.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Artivion (NYSE:AORT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to our
Artivion (NYSE:AORT) affirms FY2026 sales outlook from $480.000 million-$496.000 million to $480.000 million-$496.000 million vs $486.232 million estimate.